ROSEN, A TOP-RANKED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between May 7, 2025, and July 28, 2025, of the September 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Novo Nordisk securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by September 30, 2025, to serve as lead plaintiff [2] - The lawsuit alleges that defendants made misleading statements about Novo Nordisk's growth potential while concealing material adverse facts [4] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [3] Group 3: Case Allegations - The lawsuit claims that Novo Nordisk overstated its growth potential and the likelihood of patients switching to its branded alternatives, leading to investor damages when the true information became public [4]